Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3550
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lymphoma, Pancreatic Cancer and Prostate Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer.

    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lymphoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
Active Biotech
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Ardana
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioNumerik
BioSante
Biostar
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
Cancer Advances
Cancer Research Technology
Cel-Sci
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
CompleGen
Cornerstone Pharmaceuticals
Cosmo Bioscience
CritiTech
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
ECI
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Favrille
Ferring
FibroGen
Forma Therapeutics
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Johnson & Johnson
Kadmon
Karo Bio
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protgen
Q Chip
QLT
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
SBIO
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Synageva BioPharma
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UMN Pharma
Unigene
United Biomedical
Vaccinex
Vaxon Biotech
VaxOnco
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroMed
ViroTarg
VM Discovery
XBiotech
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEG-35156
AEZS-108
afatinib
aflibercept
AGS-1C4D4
alemtuzumab
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
APC-100
APR-246
apricoxib
ARC-100
ARQ-197
atrasentan
AVX-701
bafetinib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
brivudine
buserelin
Cabozantinib
capecitabine
carlumab
catumaxomab
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
conatumumab
CPI-613
CRLX-101
custirsen
dalotuzumab
danusertib
dasatinib
DCVax-prostate
degarelix
denileukin diftitox
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
elliptinium acetate
eniluracil
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fulvestrant
galiximab
ganitumab
gataparsen
GDC-0980
gefitinib
goserelin
GSK-1120212
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
IMP-321
inecalcitol
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukins
intetumumab
ipilimumab
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
masitinib
MCS-110
MDV-3100
MetXia
mitoxantrone
MKC-1
MLN-8237
mocetinostat
motexafin gadolinium
Nab-docetaxel
nadroparin
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
orteronel
OTS-102
ozarelix
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
pixantrone
plitidepsin
PLX-3397
pralatrexate
ProstAtak
PROSTVAC
PRX-302
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
razoxane
Reditux
retaspimycin
Rexin-G
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
RX-0201
sagopilone
sargramostim
SB-939
selumetinib
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
ß-lapachone
sunitinib malate
TAK-448
talminogene laherparepvec
tandutinib
tasquinimod
tegafur + uracil
temsirolimus
Tenarad
teniposide
tigatuzumab
tocilizumab
TOK-001
toremifene citrate
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vismodegib
volociximab
WX-671
YM-155
Z-360
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer.
    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Colorectal Cancer, Leukemia and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Pancreatic Cancer. Learn More


Target Atlas in Mesothelioma: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More